Semaglutide is developed by Novo Nordisk and is marketed under several trade names, including Ozempic, Wegovy and Rybelsus
The rarity of this case, as well as its diagnostic difficulty and severity, demonstrates the importance of such reports, so that the disease becomes more widely known among healthcare professionals, especially dermatologists who conduct ongoing follow-up of patients with NF1, those primarily affected by the tumor
Following months of litigation and policy changes, the framework for compounded tirzepatide has changed significantly since early 2025, affecting what options may be available to patients seeking affordable alternatives
We only use options that are appropriate and permitted, and we monitor every patient with labs. Robin Davis, MSN, ARNP, FNP-BC Book a consultation to review safe, supervised options for your goals
At the time of writing this review, only Zydus Cadilas new drug application for Saroglitazar had been approved (2020) for NASH therapy in India